Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexavac
- Development stage
- Discontinued
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hexavac was a hexavalent combination vaccine developed by Aventis Pasteur MSD for the primary and booster immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by *Haemophilus influenzae* type b (Hib). It contained diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxoid and filamentous haemagglutinin), recombinant hepatitis B surface antigen, inactivated poliovirus (types 1, 2, and 3), and Hib capsular polysaccharide conjugated to tetanus protein. Authorized in the European Union in 2000, the vaccine was suspended in 2005 and subsequently withdrawn from the market due to concerns regarding the long-term immunogenicity of its hepatitis B component, specifically a potential decrease in protection over time compared to other vaccines.
- Brand names
- Hexavac
- Other names
- DTPa-HBV-IPV-Hib vaccineHexavalent vaccine
02
Targets
PRNP (Cellular Prion Protein)FHA (Filamentous hemagglutinin)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)TT (Tetanus toxoid)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Hexavac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hexavac.